Holen Sie sich die Stockscreener-App
106.38
0.97%
-1.04
Handel nachbörslich:
110.25
3.87
+3.64%
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Guardant Health: Q4 Earnings Snapshot - theheraldreview.com
Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales - Finviz
Guardant Health (GH) Shares 2026 Financial Outlook with Improved Margins - GuruFocus
GH Reports Strong Q4 Revenue, Highlights Future Growth Prospects - GuruFocus
Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results - MarketBeat
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook - Yahoo Finance Singapore
Guardant Health earnings up next: Can Shield growth offset losses? By Investing.com - Investing.com Canada
GSA Capital Partners LLP Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (NASDAQ:GH) Rating Increased to Strong-Buy at Robert W. Baird - MarketBeat
Guardant Health, Inc. $GH Shares Bought by Eagle Health Investments LP - MarketBeat
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow - Finviz
Guardant Health Q4 2025 Earnings Report Date & Analyst ForecastsNews and Statistics - IndexBox
What Makes Guardant Health (GH) a Good Healthcare Holding - Finviz
Guardant Health (GH): Baird Initiates Coverage with Outperform R - GuruFocus
Baird initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com South Africa
Baird initiates Guardant Health stock coverage with outperform rating - Investing.com
North America Liquid Biopsy Market to Reach US$ 5110.34 Million - openPR.com
Guardant Health, Inc. (GH) Stock Analysis: Riding the 19.45% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Published on: 2026-02-14 21:22:46 - mfd.ru
A Look At Guardant Health (GH) Valuation As New ctDNA Study Supports Guardant Reveal In Colon Cancer - Yahoo Finance
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why (GH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Cancer Profiling Market Size, Share | Growth Report [2034] - Fortune Business Insights
Top Cancer Stocks for 2026 and How to Invest - The Motley Fool
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open - Yahoo Finance
GoFundMe for James Van Der Beek’s family surpasses $1.5M in less than 24 hours - Austin American-Statesman
Guardant Health Shares Slide as Principal Cuts Stake and Insiders Sell - CryptoRank
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Guardant Health, Inc. $GH Shares Sold by Principal Financial Group Inc. - MarketBeat
Travel Stocks: How does Guardant Health Inc compare to its peersJuly 2025 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Guardant Health Inc (GH) Trading Down 4.5% on Feb 11 - GuruFocus
Minimal Residual Disease Testing Market Poised for Rapid Growth - openPR.com
Aug Momentum: Is now the right time to enter Guardant Health IncJuly 2025 Fed Impact & Verified Stock Trade Ideas - baoquankhu1.vn
New York State Common Retirement Fund Has $4.77 Million Stake in Guardant Health, Inc. $GH - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Lowers Position in Guardant Health, Inc. $GH - MarketBeat
A Congress Member Sold Up To $125K In McDonald's Stock: Here's What You Need To Know - Benzinga
ETF Watch: Is now the right time to enter Guardant Health Inc2025 Volume Leaders & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Guardant Health to Participate in Upcoming Investor ConferencesFebruary 3, 2026 - BioSpace
Precision oncology firm Guardant lines up four investor talks - stocktitan.net
Guardant Health ctDNA test sets new standard in cancer detection - Traders Union
Guardant Health guides Q4 and FY25 revenue above consensus - MSN
Understanding Momentum Shifts in (GH) - Stock Traders Daily
Merck Eyes Post Keytruda Growth With Eikon Stake And Guardant Pact - Yahoo Finance
Guardant Health (GH) Study Highlights Advancements in Colon Canc - GuruFocus
Guardant Health, Inc. (GH) Stock Analysis: A Precision Oncology Pioneer with 9.82% Upside Potential - DirectorsTalk Interviews
ctDNA blood test better predicts colon cancer recurrence than standard staging - Investing.com
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions - Business Wire
Blood test flags colon cancer patients most likely to see disease return - Stock Titan
Aug Intraday: Can Guardant Health Inc benefit from deglobalizationWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Knights of Columbus Asset Advisors LLC Takes Position in Guardant Health, Inc. $GH - MarketBeat
Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration - Yahoo Finance
UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating - marketscreener.com
Should You Buy Guardant Health Before Feb. 19? - The Globe and Mail
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
Guardant Health, Inc. $GH Shares Bought by Federated Hermes Inc. - MarketBeat
Merger Talk: What are the future prospects of Guardant Health IncWeekly Loss Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Risk Analysis: Does Tripadvisor Inc have declining or rising EPSJuly 2025 Reactions & Precise Buy Zone Tips - baoquankhu1.vn
Guardant Health Inc (GH) Shares Down 3.74% on Jan 28 - GuruFocus
0.95%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):